Discover GPC3 Recombinant Antibody: Essential Insights for Researchers

GPC3 recombinant antibody from Alpha Lifetech Incorporation is a highly specialized and innovative tool designed for researchers focused on cancer research and regenerative medicine. GPC3 (Glypican-is a cell surface Protein that plays a critical role in cancer progression, particularly in hepatocellular carcinoma and various other tumors. This recombinant antibody is engineered to offer exceptional specificity and affinity for GPC3, enabling precise targeting in experimental applications, With a high-quality and reliable performance, this antibody facilitates a wide range of assays including Western blotting, immunohistochemistry, and ELISA. Researchers can leverage this product to gain valuable insights into GPC3's biological functions, contributing to the development of targeted therapies and diagnostic tools for cancer treatment, Alpha Lifetech Incorporation’s commitment to quality ensures that each unit of GPC3 recombinant antibody undergoes rigorous testing, providing the research community with dependable resources needed to advance their work. Unlock new possibilities in your research with this cutting-edge antibody

Hot Selling Product

ALP64505-Recombinant Human CD24 Protein, mFc Tag

ALP64533-Recombinant Mouse Siglec-15 /CD33L3 Protein, His Tag

ALP64511-Recombinant Cynomolgus Monkey TNFRSF17/BCMA Protein, His Tag

ALP64513-Recombinant Human TNFRSF17/BCMA Protein, His Tag, Flag Tag

ALP64515-Recombinant Human CD73 Protein, Fc Tag

ALP64517-Recombinant Human CD223/LAG3 Protein, His Tag, Avi Tag

China’s Best-Selling GPC3 recombinant antibody Service Backed by Expertise Global Reach

In the ever-evolving landscape of biopharmaceuticals, the demand for high-quality antibodies is paramount. At Alpha Lifetech Inc., we take pride in being at the forefront of this demand with our GPC3 recombinant antibody service, known for its exceptional quality and reliability. Our team, comprised of seasoned scientists specializing in membrane protein production, nanobody discovery, and monoclonal development, ensures that every product meets the highest scientific standards. With a portfolio that includes nearly 10,000 top-tier reagents, cytokines, and drug target antibodies, we are equipped to support research and therapeutic applications across the globe. Our GPC3 recombinant antibody is specifically designed to cater to the needs of researchers and developers focused on cancer biology and therapeutic innovations. Backed by our expertise and a commitment to quality, our service stands out in a crowded marketplace. What sets us apart is not just our comprehensive product offerings, but our global reach. We understand the importance of timely delivery and responsiveness in today’s supply chain dynamics, ensuring that our customers receive the necessary tools to advance their projects. With Alpha Lifetech, global partners can leverage our state-of-the-art solutions, accelerating their research and development efforts while achieving superior results. Join us in exploring the benefits of our GPC3 recombinant antibody service and discover how Alpha Lifetech Inc. can be your trusted partner in navigating the complexities of biologic therapies and research. Together, we can advance science and healthcare on a global scale, delivering impactful solutions that matter.

China’s Best-Selling GPC3 Recombinant Antibody Service Backed by Expertise Global Reach

Service Type	Application	Target Market	Lead Time (Weeks)	Price Range (USD)
Custom Antibody Production	Immunoassays, Western Blotting	Research Institutions	8-12	2000 - 5000
Monoclonal Antibody Development	Diagnostics, Therapeutics	Pharmaceuticals	12-16	5000 - 10000
Polyclonal Antibody Production	ELISA, Immunohistochemistry	Biotechnology Firms	6-10	1500 - 4000
Recombinant Antibody Generation	Therapeutic Development	Clinical Labs	10-14	3000 - 8000

Global Demand for Recombinant Antibodies in 2023

The demand for recombinant antibodies has shown significant growth across different regions in 2023. As depicted in the bar chart, Asia leads the global market with a demand of 600,000 units, indicating the region's robust biopharmaceutical industry and research activities. North America follows closely with 500,000 units, reflecting the presence of established biotech companies and universities focusing on innovation in antibody therapies. Europe shows a strong demand of 400,000 units as well, driven by advanced healthcare systems and research funding. Latin America and the Middle East present smaller but notable demands of 200,000 and 150,000 units respectively, highlighting emerging opportunities for growth in these regions. Understanding this data can help stakeholders identify targeted strategies for market expansion and resource allocation in the competitive landscape of recombinant antibodies.